

5-plex Blood Biomarker Panel For Alzheimer's Disease Staging



Noah Elder¹, Hien Nguyen¹, Jason Wan¹, Edward Wilson², Robert Lin¹
¹Taudia, Inc., San Carlos, CA, USA, ²Brown University, Providence, RI, USA

Introduction

Background:
Combination of multiple blood-based biomarkers provide a cost-effective, minimally invasive tool for Alzheimer's disease staging.


Objective:
Create a 5-marker panel to quantify plasma pTau-217, Aβ1-40, Aβ1-42, NfL and GFAP to create biomarker profiles to enable cost-effective and scalable disease staging.

What is SPLASH?

Solid Phase Ligation Assay with Single wash

a) Incubate b) Wash c) Quantify

Figure 1. SPLASH Workflow to quantify low-abundance biomarkers. (a,b,c) SPLASH workflow quantifies protein with qPCR.



Analytical Performance

Standard Curves

Figure 3. Standard Curves. Standard curves of all 5 targets of the panel.

Summary

- All 69 samples were detectable for all targets
- AD+ samples displays profiles that possibly suggest biomarker progression
- SPLAH enables scalable biomarker profiling that could enable cost-effective disease staging

Any questions? Please reach out to hello@taudia.com or find us at Booth #1209